Editorial

Neurodegeneration: diseases of the cytoskeleton?

The identification of a number of genes associated with hereditary neurodegenerative disorders has revealed important clues to pathophysiology. Emerging evidence suggests that mutations contributing to disease are associated with dysfunction of cytoskeletal components that influence vesicular biogenesis, vesicle/organelle trafficking and synaptic signaling. In most familial cases of neurodegenerative disorders, dysfunction of the cytoskeleton results from mutations that alter the conformation and result in accumulation of the affected gene product. The data suggest a mechanism by which cytoskeletal disruption initiates a cascade of events including mitochondrial dysfunction and oxidative stress that, ultimately, activates the DNA damage response.

This editorial, introducing three reviews on neurodegeneration, summarizes current data that link the neurodegeneration in a number of distinct diseases to dysfunction of the cytoskeleton as an underlying cause of cell death. Defects of the cytoskeleton may be a common feature contributing to neurodegeneration.

Alzheimer's disease (AD)

The most common form of dementia occurring in mid-to-late life is Alzheimer's Disease (AD).1 Late onset AD is influenced by the genetic risk-factor apolipoprotein E (APOE).2 However, most of the early onset, familial forms of AD are caused by mutations associated with amyloid precursor protein (APP), and the presenilins (PS).1,2 Inherited mutations located on chromosomes 14 and 1 are associated with presenilins 1 (PS1) and 2 (PS2).3,4 Presenilins are membrane bound proteins that participate in the Notch-like cleavage of the APP protein within its b-amyloid region.5 Missense mutations in PS1 and PS2 have been shown to selectively increase the production of the Ab42 cleavage product relative to more easily degraded Ab40 product.5 In human cells, PS cleavage of APP occurs on the surface of recycling endosomes that originate at the trans-Golgi and fuse with the plasma membrane.6 Localization within transport vesicles may account for both intracellular production of Ab42 peptide and the secretion of the Ab peptides in the extracellular space. The decreased solubility and tendency to aggregate increases the lifetime of the Ab42 peptide and results in its accumulation in extracellular plaques.1,2,7 The function of PS1 and PS2 as gamma-secretase-like enzymes have been established.8 Cleavage by PS1 and PS2 occurs by the juxtaposition of two aspartate residues in the intramembrane region of the receptor.9 Interestingly, the mechanism may involve cell-cell adhesion. Recently, an interacting partner of PS1 was found to be delta-catenin, an adheren junction protein involved with cell motility.10 Cell motility is associated with a massive restructuring of the actin cytoskeleton.11 Therefore, it is possible that defects in PS or aggregation of Ab may stimulate structural alterations in the cytoskeleton of neurons preceding the formation of fibril-containing dystrophic neurites associated with senile plaques.12

A fundamental alteration of the cytoskeleton as an underlying cause for AD may, in part, explain why, despite their abundance, accumulation of APP and plaque formation cannot be definitively confirmed as a causative event in AD. Transgenic animals that overexpress the mutant APP protein form plaques but do not display neuronal death.13 These data suggest that plaque formation per se is insufficient to cause disease, and other factors must play a role in human pathophysiology. Neuropathology of AD is defined by accumulation of another form of insoluble neurofibrillary tangles (NFT). NFT are fibrillar structures comprising largely tau, a microtubule binding protein that stabilizes the microtubule tracts necessary for vesicular trafficking, endo- and exo-cytosis and axonal polarity. No tau mutations have yet been identified in AD families. Although the relationship between tau, NFT and APP remains to be elucidated, it is possible that defects may influence aggregation of tau protein leading to impairment or misdirection of recycling endosomes that contain the APP protein. Tau forms up to six different isoforms by alternative splicing, and all six isoforms have been found in NFTs.14 Tau in NFT is typically hyperphosphorylated and, in this state, tubulin assembly is impaired. Hyperphosphorylated forms of tau have lower binding affinities to microtubules and possibly destabilize them.15 However, hyperphosphorylated forms of tau fail to form fibrils16 in vitro unless sulphated aminoglycans such as heparin sulfate are present.17 Interactions or modifications of microtubules may facilitate fibril formation. As discussed below, modifications of tubulin by nitration are also associated with motor neuron loss in Amyotrophic lateral sclerosis (ALS).

In summary, known susceptibility genes in AD have a direct influence on the microtubule or actin filaments that govern neuronal shape and size and/or movement of vesicle/organelle traffic along the neurite. PS1 and PS2 may exacerbate secretory defects that depend on an intact cytoskeleton resulting in the accumulation of APP-derived peptides as a hallmark of disease.

Tauopathies

Filamentous tau protein and/or microtubule defects are also associated with a range of neurodegenerative disorders known as tauopathies.18 Tauopathies are generally characterized by the presence of NFT and the absence of neuritic plaques. As with AD, NFT comprise either mutated tau (in the case of frontotemporal dementia and parkinsonism linked to chromosome 17 (FTDP17)),19 or hyperphosphorylated tau protein.18 In addition to AD, recent evidence indicates that NFT are associated with Picks's Disease, FTDP17, cortico-basal degeneration, progressive supranuclearpalsy, and amyotropic lateral sclerosis/parkinsonism-dementia complex of Guam, among others.18 As it stands, however, the sole set of known mutations in tau are associated with FTDP17. In the C-terminal portion of tau, three imperfect repeats are present and each contains a binding domain to microtubules.20 Several mutations in exon 10 alter the ratio of microtubule-binding domains from three to four repeats.20 The four-repeat form of tau binds more strongly to microtubules and tends to aggregate more rapidly than the three-repeat form. NFT may result from polymerization of free tau subunits thus depleting the amount of tau available for binding. Mice null for tau shows little phenotype21 while mice overexpressing the four-repeat form of tau display axon abnormalities but no NFTs.22 These data indicate that severe effects on microtubule stability are unlikely to account for disease. However, subtle differences in stabilization of microtubules may play an important and common component for neuronal survival over a lifetime.

Parkinson's disease (PD)

In addition to the FTDP17 mutation in tau, Parkinson's dementia is associated with defects in two other gene products, synuclein located on chromosome 4 and parkin located on chromosome 6. Little is known about Parkin other than that it is widely expressed in rat brain and particularly associated with substantia nigra.23 A-synuclein is a 14 kDa protein of unknown function that is located in the presynaptic terminal of the neuron.24 Although the function of the gene products is unknown, a-synuclein is a prominent component of Lewy bodies and forms a similar fibrillar structure as tau in NFT.25 Early onset of Parkinson has been associated with two point mutations in a-synuclein that both increase the rate of fibril formation in vitro.25 Interestingly, a-synuclein shares sequence homology with 14-3-3 proteins that are a family of cytoplasmic chaperones.26 Further, a-synuclein shares physical association with some targets of 14-3-3 proteins including PKC, BAD and ERK.26 Similar to tau protein, a-synuclein is highly phosphorylated when present in fibrillar Lewy bodies. The kinases that modify synuclein are not known. However, it is possible that a-synuclein itself may function as a molecular chaperone whose mutated form can promote its own aggregation and hyper-phsophorylation. Although not detected in huntingtin-containing aggregates in vivo, aggregation of huntingtin can be facilitated by the presence of a-synuclein27 suggesting there may be similarities in the mechanism of pathophysiology.

Amyotropic lateral sclerosis (ALS)

Mutations in the copper-zinc superoxide dismutase (SOD1) are known to underlie 2% of familial cases of ALS.28 Superoxide dismutase is an enzyme that scavenges oxygen free radicals and protects cells from oxidative damage. Initially, mutations in SOD were predicted to alter the enzymatic properties of this protein. However, SOD null mice do not develop disease29 and expression of mutated SOD isoforms in some transgenic mice developed disease without change in or even elevation of SOD activity.30 Instead, recent evidence indicates that SOD mutations may be directly linked to defects in both cytoskeleton components and vesicular transport motors. Aggregates containing both neurofilament and kinesin are hallmarks of ALS suggesting that these targets may be sequestered in disease. Kinesin and dynein facilitate transport of organelles along microtubules in an anterograde and retrograde direction, respectively.31 In ALS, there is not only selective loss of kinesin motors but there is also measurable slowing of axonal transport in motor neurons.32 The data indicate that impairment of slow axonal transport may be an early event in ALS pathophysiology.32 Slow transport is associated with movement along the axon of structural elements and cytoplasmic proteins including neurofilaments.33 The role of SOD in this process is not entirely clear. However, recent evidence indicates there may be disruption of tubulin by nitration near the dynactin binding site in motor neurons.34 Nitration occurs by the formation of peroxynitrite that can modify tyrosine residues on the aromatic ring.35 Since the role of SOD is to prevent peroxynitrite and ROS formation, it has been speculated that SOD may cause nitration in motor neurons that will destabilize microtubule tracts. Nitration of tubulin alters the rate of tubulin polymerization in microtubules and has the potential to interfere with the tubulin interaction with the dynein motor. Thus, impairment of oxygen scavenging function of SOD may be a direct link between oxidative stress and transport defects along microtubules.

Polyglutamine disease

Eight progressive neurodegenerative disorders result from CAG expansion encoding a polyglutamine tract.36,37,38 The exact mechanism for disease is unknown for any of the polyglutamine diseases. However, protein-protein interactions leading to insoluble bodies called inclusions have been identified in human disease brains in all of these diseases. Both cytoplasmic and nuclear inclusions appear to mark the pathology of polyglutamine disorders but inclusion themselves are unlikely to be causative in disease.39 Rather, it is the targets of aggregation that appear to be associated with toxicity. The number of important targets is unknown. However, both nuclear and cytoplasmic pathways may play a role in toxicity, depending on the normal subcellular localization of the respective protein. For example, ataxin-1, the gene product underlying spinocerebellar ataxia type I (SCAI), normally resides in the nucleus. Ataxin-1 is actively directed to the nucleus by a functional nuclear localization signal (NLS),40 and altering the NLS abrogates nuclear transport. Transgenic animals expressing ataxin-1 with expanded polyglutamine and functional NLS develop ataxia,41 but transgenic animals expressing expanded ataxin-1 without functional NLS develop neither pathology nor nuclear inclusions.40 The expanded ataxin-1 (with NLS) is known to alter the subnuclear localization of leucine acidic nuclear protein expressed highly in the affected Purkinje cells of the cerebellum.41,42 Aggregation and sequestration of nuclear targets by the mutant protein may lead directly to improper DNA surveillance, mounting of a damage response and cell death.

However, for other polyglutamine proteins including the human Huntington's protein (htt) and spinocerebellar ataxia type 3 (SCA3), the protein normally resides in the cytoplasm and both are associated with primarily cytoplasmic inclusions in adult onset cases.43,44,45,46,47 Htt, for example, has a primarily cytoplasmic distribution in perikarya, axons, dendrites and some nerve terminals.48,49 Yeast two-hybrid experiments reveal that huntingtin-interacting proteins tend to be (although not exclusively) cytoplasmic. These include ubiquitin conjugating enzyme, E2-25K,50 SH3GL3 proteins,51 a brain specific protein, HAP-1 (Huntingtin associated protein),52 the cytoskeletal associated protein, HIP1,53 tubulin,54 dynactin,55,56 WW domain proteins,57 the cytoskeletal, ras-related protein Duo,58 and SlaI, a cytoskeletal assembly protein involved in the nucleation of actin microfilaments.59 The latter may be associated with clathrin coated vesicles.60 Although nuclear events are also associated with htt pathophysiology39 most of the associated proteins represent components of the vesicular transport machinery or cytoplasmic tracts on which they move. Therefore, it is possible that cytoplasmic aggregation and the cytoskeleton defects may play a role in toxicity.

Among the important cargo that is transported along the cytoskeleton is mitochondria. Thus, disruption of the cytoskeleton may lead to cell death by impairing the function of MT and energy depletion in the cell. As discussed below, disruption of mitochondrial function and glucose metabolism has been proposed to mediate neuronal death in many neurodegenerative diseases. Perhaps, the most direct example of these is Friedreich's Ataxia (FRDA).37 FRDA gene product encodes a protein that binds to the MT membrane and regulates the concentration of iron in MT.61 GAA expansion in the gene62 is thought to cause transcriptional shut-down and loss of the FRDA gene product37 that results in iron accumulation in MT, MT dysfunction and cell death.61 Dysfunction of MT has also been implicated in HD. In rats, systemic administration of the mitochondrial complex II inhibitor 3-nitropropionic acid causes neurobehavioral and pathological abnormalities consistent with HD; and, in HD patients, the caudate has severe deficiencies in mitochondrial complexes II and III.63,64 It has been suggested that association of the htt expanded gene product with mitochondrial respiratory chain isoenzymes may account for the pathogenic effects of this polyglutamine disorder. Recent studies support this hypothesis and indicate that the membrane potential of the MT is diminished in fibroblast from HD patients.65 It is known that striatal and cerebral glucose metabolism are decreased and precede bulk tissue loss in HD patients. Furthermore, HD protein binds glyceraldehyde-3-phosphate dehydrogenase (GAPDH), suggesting that mutant HD protein may inactivate this enzyme.

In conclusion, neurons cannot synthesize proteins along the axon and are particularly dependent on vesicular transport to provide these. Most, if not all of the neurodegenerative disorders discussed above have some defect in the cytoskeletal tracts that either sustain neuronal shape and trafficking or a defect in the motors that provide energy for vesicle/organelle movement including MT. These events may be responsible for energy depletion in the neuron as well as provide a source for oxidative damage in the cell. Oxidative damage may lead directly to 8-OH guanine modification66 and a DNA damage response that ultimately kills the cell. Alternatively, in the case of the nuclear polyglutamine proteins, there may be direct nuclear pathway that involves inactivation of the DNA surveillance factors themselves. Several reviews that follow in this issue not only report on additional neurodegenerative disorders but also provide ideas on a mechanism by which neurons might mount a DNA damage response. Both Morrison and Kinoshita67 and Miller et al.68 describe the involvement of p53, and its family member p73, in regulating neuronal apoptosis in both the developing and injured, mature nervous system. This includes DNA damage, ischemia and excitotoxicity, as well as neurodegenerative diseases in general. Finally, Aguzzi and Hepper69 review the current understanding of the pathogenesis of prion diseases (spongiform encephalopathies).

References

  1. 1.

    and . 1999 Alzheimer's disease. Nature 398: 466–467

  2. 2.

    , and . 2000 The beta-amyloid precursor protein and its derivatives: from biology to learning and memory processes. Rev Neurosci. 11: 75–93

  3. 3.

    , , , , , , , and . 1995 Cloning of a gene bearing missense mutations in early-onset familial Alzheimer's disease. Nature 375: 754–760

  4. 4.

    , , , , , , , , , . 1995 Candidate gene for the chromosome 1 familial Alzheimer's disease locus. Science 269: 973–977

  5. 5.

    , , , , , , , and . 1992 Mutation of the beta-amyloid precursor protein in familial Alzheimer's disease increases beta-protein production. Nature 360: 672–674

  6. 6.

    , , and . 2000 Mutant presenilin 1 increases the levels of Alzheimer amyloid beta-peptide Abeta42 in late compartments of the constitutive secretory pathway. J. Neurochem. 74: 1878–1884

  7. 7.

    , , , , and . 1999 Intracellular site of gamma-secretase cleavage for Abeta42 generation in neuro 2a cells harbouring a presenilin 1 mutation. Eur. J. Biochem. 267: 2036–2045

  8. 8.

    . 2000 Notch and presenilins in vertebrates and invertebrates: implications for neuronal development and degeneration. Curr. Opin. Neurobiol. 10: 50–57

  9. 9.

    , , , and . 2000 The transmembrane aspartates in presenilin 1 and 2 are obligatory for gamma-secretase activity and amyloid beta-protein generation. J. Biol. Chem. 275: 3173–3178

  10. 10.

    and . 1999 Isolation of human delta-catenin and its binding specificity with presenilin 1. Neuroreport 10: 563–568

  11. 11.

    and . 2000 Acting like actin. The dynamics of the nematode major sperm protein (msp) cytoskeleton indicate a push-pull mechanism for amoeboid cell motility. J. Cell Biol. 149: 7–12

  12. 12.

    , , , and . 1991 Deposition of beta/A4 protein along neuronal plasma membranes in diffuse senile plaques. Acta Neuropathologica 83: 21–29

  13. 13.

    , , , , , , , , , , , , , , , and . 1995 Alzheimer-type neuropathology in transgenic mice overexpressing V717F beta-amyloid precursor protein. Nature 373: 523–527

  14. 14.

    , , , and . 1989 Multiple isoforms of human microtubule-associated protein tau: sequences and localization in neurofibrillary tangles of Alzheimer's disease. Neuron 3: 519–526

  15. 15.

    , , , and . 1999 Phosphorylation that detaches tau protein from microtubules (Ser262, Ser214) also protects it against aggregation into Alzheimer paired helical filaments. Biochemistry 38: 3549–3558

  16. 16.

    , , and . 1997 Alzheimer-like changes in microtubule-associated protein Tau induced by sulfated glycosaminoglycans. Inhibition of microtubule binding, stimulation of phosphorylation, and filament assembly depend on the degree of sulfation. J. Biol. Chem. 272: 33118–33124

  17. 17.

    , , , , and . 1996 Assembly of microtubule-associated protein tau into Alzheimer-likefilaments induced by sulphated glycosaminoglycans. Nature 383: 550–553

  18. 18.

    . 2000 Untangling tau-related dementia. Hum. Mol. Gen. 9: 979–986

  19. 19.

    , , , , , , , , , and . 1999 FTDP-17: an early-onset phenotype with parkinsonism and epileptic seizures caused by a novel mutation. Ann. Neurol. 46: 708–715

  20. 20.

    , and . 1992 Structure and novel exons of the human tau gene. Biochemistry. 31: 10626–10633

  21. 21.

    , , , , , , , , and . 1994 Altered microtubule organization in small-calibre axons of mice lacking tau protein. Nature 369: 488–491

  22. 22.

    , , , , , , , , , , and . 1999 Prominent axonopathy in the brain and spinal cord of transgenic mice overexpressing four-repeat human tau protein. Am. J. Pathol. 155: 2153–2156

  23. 23.

    , and . 2000 Cloning and distribution of the rat parkin mRNA. Brain Res. Mol. Brain Res. 75: 345–349

  24. 24.

    , , , , and . 2000 Synphilin-1 is present in Lewy bodies in Parkinson's disease. Ann. Neurol. 47: 521–523

  25. 25.

    , , and . 2000 Membrane association and protein conformation of alpha-synuclein in intact neurons. Effect of Parkinson's disease-linked mutations. J. Biol. Chem. 275: 8812–8816

  26. 26.

    , , , , , and . 1999 Synuclein shares physical and functional homology with 14-3-3 proteins. J. Neurosci. 19: 5782–5791

  27. 27.

    , , , and . 2000 alpha-synuclein overexpression promotes aggregation of mutant huntingtin. Biochem. J. 346: 577–581

  28. 28.

    , , , and . 2000 Mechanisms for neuronal degeneration in amyotrophic lateral sclerosis and in models of motor neuron. Int. J. Mol. Med. 5: 3–13

  29. 29.

    , , , , , , , , , , and . 1996 Motor neurons in Cu/Zn superoxide dismutase-deficient mice develop normally but exhibit enhanced cell death after axonal injury. Nature Genetics 13: 43–47

  30. 30.

    , , , , , , , , , , et al.1994 Motor neuron degeneration in mice that express a human Cu,Zn superoxide dismutase. Science 264: 1772–1775

  31. 31.

    . 1998 Kinesin and dynein superfamily proteins and the mechanism of organelle transport. Science 279: 519–526

  32. 32.

    and . 1999 Slowing of axonal transport is a very early event in the toxicity of ALS-linked SOD1 mutants to motor neurons. Nature Neurosci. 2: 50–56

  33. 33.

    and . 1975 The slow component of axonal transport. Identification of major structural polypeptides of the axon and their generality among mammalian neurons. J. Cell Biol. 66: 351–366

  34. 34.

    , , , , , and . 1999 Microtubule dysfunction by posttranslational nitrotyrosination of alpha-tubulin: a nitric oxide-dependent mechanism of cellular injury. Proc. Natl. Acad. Sci. USA 96: 6365–6370

  35. 35.

    , and . 1999 Peroxynitrite studied by stopped-flow spectroscopy. Meth. Enzymol. 301: 342–352

  36. 36.

    , and . 1999 Oxidative stress in Huntington's disease. Brain Pathol. 9: 147–163

  37. 37.

    . 1999 DNA secondary structure: A common and causative factor for expansion in human disease. Proc. Natl. Acad. Sci. USA 96: 1823–1825

  38. 38.

    and . 1998 Huntington Disease. J. Neuropathol. Exp. Neurol. 57: 369–384

  39. 39.

    , , and . 1998 Huntingtin acts in the nucleus to induce apoptosis but death does not correlate with the formation of intranuclear inclusions. Cell 95: 55–66

  40. 40.

    , , , , , , and . 1998 Ataxin-1 nuclear localization and aggregation: role in polyglutamine-induced disease in SCA1 transgenic mice. Cell 95: 41–53

  41. 41.

    , , , , , , , and . 1995 SCA1 transgenic mice: a model for neurodegeneration caused by an expanded CAG trinucleotide repeat. Cell 82: 937–948

  42. 42.

    , , , , and . 1997 The cerebellar leucine-rich acidic nuclear protein interacts with ataxin-1. Nature 389: 974–978

  43. 43.

    , , , , , , , and . 1994 A nuclear factor containing the leucine-rich repeats expressed in murine cerebellar neurons. Proc. Natl. Acad. Sci. USA 91: 9670–9674

  44. 44.

    , , , , , and . 1997 Aggregation of huntingtin in neuronal intranuclear inclusions and dystrophic neurites in brain. Science 277: 1990–1993

  45. 45.

    , , , , , , , and . 1998 Neuronal distribution of intranuclear inclusions in Huntington's disease with adult onset. NeuroReport 9: 1823–1826

  46. 46.

    , , , , , , , , and . 1999 Nuclear and neurophil aggregates in Huntington's disease: relationship to neuropathology. J. Neurosci. 19: 2522–2534

  47. 47.

    , , , , , and . 1998 Wild-type and mutant huntingtins function in vesicle trafficking in the secretory and endocytic pathways. Exp. Neurol. 152: 34–40

  48. 48.

    , , , , , , , and . 1997 Huntingtin localization in brains of normal and Huntington's disease patients. Ann. Neurol. 42: 604–612

  49. 49.

    , , , , , , , , , , , and . 1997 Differential distribution of the normal and mutated forms of huntingtin in the human brain. Ann. Neurol. 42: 712–719

  50. 50.

    , , , , , , , , and . 1996 Huntingtin is ubiquitinated and interacts with a specific ubiquitin-conjugating enzyme. J. Biol. Chem. 271: 19385–19394.

  51. 51.

    , , , , , , , and . 1998 SH3GL3 associates with the huntingtin exon 1 protein and promotes the formation of polygln-containing protein aggregates. Mol. Cell. 2: 427–443

  52. 52.

    , , , , , , , and . 1995 A huntingtin-associated protein enriched in brain with implications for pathology. Nature 378: 398–402

  53. 53.

    , , , , , , and . 1997 HIP-1: A huntingtin interacting protein isolated by the yeast two-hybrid system. Hum. Mol. Genet. 6: 487–495

  54. 54.

    , , and . 1997 Huntington's disease gene product, huntingtin, associates with microtubules in vitro. Mol. Brain Res. 51: 8–14

  55. 55.

    , , and . 1998 Interaction of huntingtin associated protein with dynactin p150Glued. J. Neurosci. 18: 1261–1269

  56. 56.

    , , , , , , and . 1997 Huntingtin-associated protein 1 (HAP 1) interacts with the p150Glued subunit of dynactin. Hum. Mol. Genet. 6: 2205–2212

  57. 57.

    , , , , and . 1998 Huntingtin interacts with a family of WW domain proteins. Hum. Mol. Genet. 7: 1463–1474

  58. 58.

    , , , , , , , and . 1997 Huntingtin-associated protein 1 (HAP1) binds to a Trio-like polypeptide, with a rac1 quanine nucleotide exchange factor domain. Hum. Mol. Genet. 6: 1519–1525

  59. 59.

    , , and . 1999 Genetic study of interactions between the cytoskeletal assembly protein sla1 and prion-forming domain of the release factor Sup35 (eRF3) in Saccharomyces cerevisiae. Genetics. 153: 81–94.

  60. 60.

    , , , and . 1999 An actin binding protein is a novel component of clathrin-coated pits and vesicles. J. Cell Biol. 147: 1503–1518

  61. 61.

    , , , , , and . 1999 Deficit of in vivo mitochondrial ATP production in patients with Friedreich ataxia. Proc. Natl. Acad. Sci. USA 96: 10948–10949

  62. 62.

    , , , , , , , , , , , and . 1998 GAA instability in Friedreich's Ataxia shares a common, DNA-directed and intraallelic mechanism with other trinucleotide diseases. Molecular Cell. 1: 583–593

  63. 63.

    , , , and . 1996 Respiratory chain abnormal function in Huntington's disease chorea. Ann. Neurol., 39: 385–389

  64. 64.

    , , and . 1993 Evidence for impairment of energy metabolism in vivo in Huntington's disease using localized 1H NMR spectroscopy. Neurol. 43: 2689–2695

  65. 65.

    , , , , , , , and . 1999 Increased apoptosis of Huntington disease lymphoblasts associated with repeat length-dependent mitochondrial depolarization. Nature Medicine. 5: 1194–1198

  66. 66.

    , , , , and . 1999 Increased 8-oxo-dGTPase in the mitochondria of substantia nigral neurons in Parkinson's disease. Annals of Neurology. 46: 920–924

  67. 67.

    and . 2000 The role of p53 in neuronal cell death. Cell Death Differ. 7: 868–879 (this issue)

  68. 68.

    , and . 2000 Neuronal life and death: an essential role for the p53 family. Cell Death Differ. 7: 880–888 (this issue)

  69. 69.

    and . 2000 Pathogenesis of prion diseases: a progress report. Cell Death Differ. 7: 889–902 (this issue)

Download references

Acknowledgements

The author acknowledges Drs. C Spiro, J Rockwood and J Goudreau for critical reading of the manuscript. This work was supported by the Mayo Foundation, the Hereditary Disease Foundation; DK 43694-01A2 and MH-56207 from National Institutes of Health; IBN 9728120 from National Science Foundation (to CT McMurray).

Author information

Affiliations

  1. Department of Molecular Pharmacology and Experimental Therapeutics, Molecular Neuroscience Program, Mayo Clinic and Foundation, Rochester, MN 55905, USA

    • C T McMurray
  2. Department of Biochemistry and Molecular Biology, Molecular Neuroscience Program, Mayo Clinic and Foundation, Rochester, MN 55905, USA

    • C T McMurray

Authors

  1. Search for C T McMurray in:

Corresponding author

Correspondence to C T McMurray.